SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (167)12/15/1999 8:43:00 PM
From: James Perry  Read Replies (1) of 370
 
Any information on the amount of royalty Boehringer Ingleheim will be obligated to pay on Promycin, if and when it is licensed? What relationship, if any, existed between Boehringer Ingleheim and Boehringer Mannheim? The latter company was acquired by Roche, and it is very memorable that Igen has been in court for the past two-three years, trying to collect the royalties that Mannheim agreed to pay them. I realize that a family of great wealth owns Boehringer, but I trust them about as far as I can throw a mule.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News